Skip to main content
. 2020 Oct 4;10(6):e181. doi: 10.1002/ctm2.181

FIGURE 8.

FIGURE 8

I‐BET151 inhibited the tumorigenicity of U87‐MG GICs in vivo. The mice were treated with intraperitoneal injection with DMSO, I‐BET151 (16 mg/kg/day) for 3 days a week. The treatment started from the 7th day after implantation and lasted for approximately 28 days. (A) Representative images of bioluminescence of mice on days 7, 14, and 28 after implantation. (B) Quantitative analysis of these bioluminescence images for the DMSO, I‐BET151 treatment groups. Data are shown as the mean ± SD, n = 6, **P < .01 compared to the control, Student's t‐test (C) The overall survival of mice in the DMSO, I‐BET151 treatment groups. Data are shown as the mean ± SD, n = 6, NS P > .05, **P < .01 compared to the control, ANOVA test. (D‐E) Representative images of the HE (× 40 magnification, scale bar = 200 µm) and IHC staining in tumor sections (× 100 magnification, scale bar = 100 µm).The three rows of HE samples are repeated data from different processing groups. The outlined sections of top images were defined as higher magnification sections below